Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

LONDON - The European Commission has authorized the use of Vocabria and Rekambys, a long-acting injectable regimen, for adolescents living with HIV-1, ViiV Healthcare, majority-owned by GSK (NYSE: GSK ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

* Value is calculated by using the current share price multiplied by the amount held.